Advanced bioactive hydrogels for the treatment of myocardial infarction

Lu, Yajie; Luo, Yuting; Zhu, Rui; Huang, Xingyuan; Bai, Shumeng

doi:10.1039/d2tb01591a

Cited by 7 publications

(5 citation statements)

References 110 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[11][12][13] In recent years, various advanced hydrogels with excellent properties have been extensively utilized in cardiac tissue engineering, and numerous studies have demonstrated their promising potential as a treatment option for MI. [14] Hydrogels not only provide necessary mechanical support during cardiac tissue repair but can also be injected into the MI site for minimally invasive treatment in situ. [15,16] In addition, hydrogels serve as an ideal delivery platform capable of loading various drugs, cells, and growth factors for targeted delivery and sustained release.…”

Section: Doi: 101002/mabi202300302mentioning

confidence: 99%

“…[54] Among these approaches, hydrogels are the preferred choice of bio-scaffold materials due to their adjustable mechanical properties, excellent biocompatibility, and multifunctionality. [14,55] Many hydrogels containing natural macromolecular materials (e.g., chitosan, gelatin, sodium alginate, decellularized matrix, etc.) have superior biocompatibility.…”

Section: Treatments Of Myocardial Infarctionmentioning

confidence: 99%

“…With the deepening of the understanding of the microenvironment after MI, a variety of hydrogels that are anti-inflammatory, antioxidant, pro-angiogenesis, and cardiomyocyte supplements have been gradually developed. [14,19] At the same time, researchers continue to explore and improve the biocompatibility and mechanical properties of hydrogels, so that it is more similar to the natural heart tissue and more Keratin, 4-Aminobenzothioamide and Pluronic F-127…”

Section: Conclusion and Future Perspectivesmentioning

confidence: 99%

“…With the deepening of the understanding of the microenvironment after MI, a variety of hydrogels that are anti‐inflammatory, antioxidant, pro‐angiogenesis, and cardiomyocyte supplements have been gradually developed. [ 14,19 ] At the same time, researchers continue to explore and improve the biocompatibility and mechanical properties of hydrogels, so that it is more similar to the natural heart tissue and more clinically safe and effective. In recent years, the application of acellular matrix hydrogels, gene‐carrying hydrogels, exosome‐carrying hydrogels, and conductive hydrogels in the treatment of MI has further broadened this field.…”

Section: Conclusion and Future Perspectivesmentioning

confidence: 99%

See 3 more Smart Citations

Hydrogels for the Treatment of Myocardial Infarction: Design and Therapeutic Strategies

Liang,

Lv,

et al. 2023

Macromolecular Bioscience

View full text Add to dashboard Cite

Cardiovascular diseases (CVDs) have become the leading global burden of diseases in recent years and are the primary cause of human mortality and loss of healthy life expectancy. Myocardial infarction (MI) is the top cause of CVDs‐related deaths, and its incidence is increasing worldwide every year. Recently, hydrogels have garnered great interest from researchers as a promising therapeutic option for cardiac tissue repair after MI. This is due to their excellent properties, including biocompatibility, mechanical properties, injectable properties, anti‐inflammatory properties, antioxidant properties, angiogenic properties, and conductive properties. This review discusses the advantages of hydrogels as a novel treatment for cardiac tissue repair after MI. The design strategies of various hydrogels in MI treatment are then summarized, and the latest research progress in the field is classified. Finally, the future perspectives of this booming field are also discussed at the end of this review.

show abstract

Section: Doi: 101002/mabi202300302mentioning

confidence: 99%

Section: Treatments Of Myocardial Infarctionmentioning

confidence: 99%

Section: Conclusion and Future Perspectivesmentioning

confidence: 99%

Section: Conclusion and Future Perspectivesmentioning

confidence: 99%

See 2 more Smart Citations

Hydrogels for the Treatment of Myocardial Infarction: Design and Therapeutic Strategies

Liang,

Lv,

et al. 2023

Macromolecular Bioscience

View full text Add to dashboard Cite

show abstract

“…Current treatments for MI include pharmaceutical therapy, medical device implants, and organ transplants; however, each has its own inherent limitations. − Injectable hydrogels have emerged as a promising translational therapeutic toward regeneration of cardiac tissue after MI. These hydrogels have the capacity to encapsulate cells and/or locally release therapeutics after injection through a syringe or catheter. , Several formulations for injection into cardiac tissue have been demonstrated as safe in animals and are in clinical trials. , Recent hydrogels engineered for cardiac tissue to reverse the adverse myocardial microenvironment include matrix metalloproteinase-responsive hydrogels, reactive oxygen species-scavenging hydrogels, and immunomodulatory hydrogels .…”

Section: Introductionmentioning

confidence: 99%

Evaluation of Tyrosine Kinase Inhibitors Loaded Injectable Hydrogels for Improving Connexin43 Gap Junction Intercellular Communication

Zheng,

Shi,

Liu

et al. 2024

ACS Appl. Mater. Interfaces

View full text Add to dashboard Cite

Myocardial infarction (MI) is one of the leading causes of death in the developed world, and the loss of cardiomyocytes plays a critical role in the pathogenesis of heart failure. Implicated in this process is a decrease in gap junction intercellular communication due to remodeling of Connexin43 (Cx43). We previously identified that intraperitoneal injection of the Pyk2 inhibitor PF4618433 reduced infarct size, maintained Cx43 at the intercalated disc in left ventricle hypertrophic myocytes, and improved cardiac function in an MI animal model of heart failure. With the emergence of injectable hydrogels as a therapeutic toward the regeneration of cardiac tissue after MI, here, we provide proof of concept that the release of tyrosine kinase inhibitors from hydrogels could have beneficial effects on cardiomyocytes. We developed an injectable hydrogel consisting of thiolated hyaluronic acid and P123-maleimide micelles that can incorporate PF4618433 as well as the Src inhibitor Saracatinib and achieved sustained release (of note, Src activates Pyk2). Using neonatal rat ventricular myocytes in the presence of a phorbol ester, endothelin-1, or phenylephrine to stimulate cardiac hypertrophy, the release of PF4618433 from the hydrogel had the same ability to decrease Cx43 tyrosine phosphorylation and maintain Cx43 localization at the plasma membrane as when directly added to the growth media. Additional beneficial effects included decreases in apoptosis, the hypertrophic marker atrial natriuretic peptide (ANP), and serine kinases upregulated in hypertrophy. Finally, the presence of both PF4618433 and Saracatinib further decreased the level of ANP and apoptosis than each inhibitor alone, suggesting that a combinatorial approach may be most beneficial. These findings provide the groundwork to test if tyrosine kinase inhibitor release from hydrogels will have a beneficial effect in an animal model of MI-induced heart failure.

show abstract

A Whole‐Course‐Repair System Based on Stimulus‐Responsive Multifunctional Hydrogels for Myocardial Tissue Regeneration

Liu,

Long,

Wang

et al. 2024

Small Methods

View full text Add to dashboard Cite

Myocardial infarction (MI) has emerged as the predominant cause of cardiovascular morbidity globally. The pathogenesis of MI unfolds as a progressive process encompassing three pivotal phases: inflammation, proliferation, and remodeling. Smart stimulus‐responsive hydrogels have garnered considerable attention for their capacity to deliver therapeutic drugs precisely and controllably at the MI site. Here, a smart stimulus‐responsive hydrogel with a dual‐crosslinked network structure is designed, which enables the precise and controlled release of therapeutic drugs in different pathological stages for the treatment of MI. The hydrogel can rapidly release curcumin (Cur) in the inflammatory phase of MI to exert anti‐apoptotic/anti‐inflammatory effects. Recombinant humanized collagen type III (rhCol III) is loaded in the hydrogel and released as the hydrogel swelled/degraded during the proliferative phase to promote neovascularization. RepSox (a selective TGF‐β inhibitor) releases from Pluronic F‐127 grafted with aldehyde nanoparticles (PF127‐CHO@RepSox NPs) in the remodeling phase to against fibrosis. The results in vitro and in vivo suggest that the hydrogel improves cardiac function and alleviates cardiac remodeling by suppressing inflammation and apoptosis, promoting neovascularization, and inhibiting myocardial fibrosis. A whole‐course‐repair system, leveraging stimulus‐responsive multifunctional hydrogels, demonstrates notable effectiveness in enhancing post‐MI cardiac function and facilitating the restoration of damaged myocardial tissue.

show abstract

Advanced bioactive hydrogels for the treatment of myocardial infarction

Abstract: Myocardial infarction (MI) is the leading causes of cardiovascular disease-related deaths. Local ischemia and cardiomyocyte death lead to a series of pathological remodeling of infarcted extracellular matrix (ECM) that are...

Cited by 7 publications

References 110 publications

Hydrogels for the Treatment of Myocardial Infarction: Design and Therapeutic Strategies

Hydrogels for the Treatment of Myocardial Infarction: Design and Therapeutic Strategies

Evaluation of Tyrosine Kinase Inhibitors Loaded Injectable Hydrogels for Improving Connexin43 Gap Junction Intercellular Communication

A Whole‐Course‐Repair System Based on Stimulus‐Responsive Multifunctional Hydrogels for Myocardial Tissue Regeneration

Contact Info

Product

Resources

About